U.S. Media Stock News

If you are wondering whether ImmunityBio's recent share price makes sense or not, you are not alone; the stock has attracted attention from investors trying to work out what a fair value might look like. The share price closed at US$2.82, with returns of 31.8% over the last 7 days, 19.5% over the last 30 days and 39.6% year to date, while the 1 year return sits at 21.6% and the 3 year return at negative 40.5%. Recent news flow around ImmunityBio has focused on its clinical pipeline and...

Concentrix (CNXC) closed out FY 2025 with Q4 revenue of US$2.6b and a basic EPS loss of US$23.83, alongside a net income loss of US$1.5b. On a trailing twelve month basis, revenue stood at US$9.8b with a net loss of US$1.3b and basic EPS of US$20.30. Over recent quarters the company has seen quarterly revenue move from US$2.4b in Q4 2024 to US$2.6b in Q4 2025. However, basic EPS shifted from US$1.73 and net income of US$111.0m in Q4 2024 to a sizable loss in the latest quarter, so the focus...

Intuit (INTU) has drawn fresh attention after BDO Canada LLP launched “BDO Powered by Intuit QuickBooks,” a joint offering that uses Intuit’s platform, automation, and AI-driven insights for Canadian small and mid-sized businesses. See our latest analysis for Intuit. The BDO partnership lands during a weaker patch for the stock, with a 1-month share price return of 9.78% decline and a year to date share price return of 3.84% decline, even as the 3-year total shareholder return of 58.20%...

If you are wondering whether Amkor Technology's current share price lines up with its underlying worth, you are not alone. This article walks through what that might look like using several valuation angles. At a last close of US$51.95, the stock has returns of 1.3% over 7 days, 17.2% over 30 days, 21.0% year to date, 108.2% over 1 year and 195.9% over 5 years. These figures may prompt questions about how much optimism or risk is now priced in. Recent coverage of Amkor has focused on its...

Earlier this month, UBS upgraded Altria Group to a buy rating, citing increased confidence in the company’s core tobacco operations and earnings visibility. UBS highlighted that cigarette volume declines may be easing and that industry conditions could become more supportive, potentially affecting how investors view Altria’s long-term cash generation and product mix. Next, we’ll explore how UBS’s view that cigarette volume declines may be easing could influence Altria’s existing investment...

If you are wondering whether Paylocity Holding's share price around US$144.74 offers good value today, it helps to separate the story from the numbers and look at what the data actually says. Over the last week the stock has recorded a 5.1% decline, while the 1 year return sits at a 24.7% decline. This may prompt questions about whether expectations or perceived risk have shifted. Recent commentary around Paylocity has focused on its position in payroll and human capital management software,...

RingCentral (RNG) has drawn fresh attention after appointing Mahmoud ElAssir to its Board of Directors, a technology and AI transformation leader currently serving as Senior Vice President and Chief Technology Officer at UnitedHealth Group. See our latest analysis for RingCentral. Against this appointment, RingCentral’s share price has been choppy, with a 1-day share price return of 3.49% decline and a 30-day share price return of 8.34% decline. The 1-year total shareholder return of 13.20%...

Netflix (NFLX) is back in focus after its latest reported figures, with investors weighing a share price near US$90 against revenue of US$43.4b and net income of US$10.4b. See our latest analysis for Netflix. At a share price of US$90.32, Netflix has seen a 24.94% 90 day share price decline even as its 1 year total shareholder return sits at 9.03% and the 3 year total shareholder return is approximately 18 times. If Netflix has you rethinking where growth and resilience might come from next,...

Dell Technologies (DELL) has put AI at the center of its story, raising its fiscal 2026 AI server sales forecast to US$25b, acquiring Dataloop, and rolling out the One Dell Way modernization program. See our latest analysis for Dell Technologies. Despite Dell’s busy year of AI focused product launches, acquisitions and the One Dell Way overhaul, momentum has cooled recently, with a 90 day share price return showing a 22.15% decline, even as the 5 year total shareholder return of 244.68%...

Recently, Tidewater outlined 2026 revenue guidance of US$1.32 billion to US$1.37 billion and confirmed it still has US$500 million available under its share repurchase authorization, against a backdrop of firmer crude oil prices and a softer U.S. jobs report that supported offshore energy sentiment. This combination of firmer long-term revenue expectations and potential capital returns has sharpened attention on how Tidewater might balance growth investment with shareholder-focused uses of...

The latest move from Cadence Design Systems (CDNS) centers on two product announcements that tie the business more tightly to AI hardware, including a new LPDDR5X memory IP solution with Microsoft as the first customer. See our latest analysis for Cadence Design Systems. Those AI focused launches come after a steady year in the market, with a 1 year total shareholder return of 9.81% and a 3 year total shareholder return of 86.77%, while the current share price sits at US$323.06. If Cadence’s...

Why Morgan Stanley Is Back On Investors’ Radar Morgan Stanley (MS) is drawing fresh attention as investors reassess its recent share performance in the context of its global wealth management, institutional securities, and investment management franchises. See our latest analysis for Morgan Stanley. Recent trading has been a bit choppy, with a 1-day share price return of a 2.04% decline and a 7-day share price return of a 2.66% decline, while a 90-day share price return of 12.36% alongside a...

Why the 24/7 Care upgrade matters for Teladoc Health stock Teladoc Health (TDOC) has rolled out a nationwide upgrade to its 24/7 Care service, expanding virtual urgent care to more conditions, adding real-time specialist consults, and integrating preventive care and prescription benefit checks. See our latest analysis for Teladoc Health. Even with the 24/7 Care upgrade and a recent appearance at the J.P. Morgan Healthcare Conference, Teladoc Health’s share price has been weak, with a 7 day...

Federal housing policy is back in focus after President Donald Trump directed the purchase of US$200b in mortgage bonds, a move aimed at lowering borrowing costs and directly affecting demand for builders such as D.R. Horton (DHI). See our latest analysis for D.R. Horton. The policy driven rebound that lifted D.R. Horton after the US$200b mortgage bond announcement comes on top of a 7 day share price return of 11.31% and a year to date share price return of 10.38%, while the 5 year total...

In early January 2026, Omnicom Group Inc. unveiled the next generation of its Omni marketing intelligence platform, integrating advanced AI, Acxiom RealID-powered identity data spanning 2.60 billion verified IDs, Flywheel Commerce Cloud signals, and autonomous agent systems into a unified operating system for marketers. This upgraded Omni platform uniquely combines one of the industry's most extensive consumer identity infrastructures with AI-native creative and media tools, aiming to give...

Wondering whether UP Fintech Holding offers genuine value at its current price, or if the recent excitement has already been priced in? This article breaks down what the numbers are saying about the stock. The share price sits at US$9.52 after a 7 day return of an 8.8% decline, a 30 day return of 3.0%, a year to date return of an 8.8% decline, a 1 year return of 54.5% and a 3 year return of 138.0%, while the 5 year return stands at a 36.2% decline. Recent coverage around UP Fintech Holding...

Constellation Brands (STZ) is back in focus after third quarter results topped expectations even as sales and profits softened, with management leaning on pricing, cost savings, dividends, and buybacks to steady the story. See our latest analysis for Constellation Brands. The latest results and capital return updates come after a mixed stretch for investors, with a 90 day share price return of 10.27% and an 8.49% year to date share price gain set against a 1 year total shareholder return of...

Why Waste Connections stock is drawing fresh attention Waste Connections (WCN) is back on investors’ radar after recent share price weakness, with the stock showing negative returns over the past week, month, past 3 months and year despite positive multi year performance. See our latest analysis for Waste Connections. The recent 6.5% 7 day share price decline and 6.4% year to date share price return have taken some momentum out of Waste Connections, even though the 5 year total shareholder...

Earlier this month, The Trade Desk announced that major publishers including AccuWeather, BuzzFeed, the Guardian, Hearst, Newsweek, People Inc., and Ziff Davis are backing its new OpenAds auction environment, which aims to give publishers and sellers a more direct, transparent way to run digital ad auctions. This broad publisher support highlights growing industry demand for higher-integrity programmatic auctions and positions OpenAds as a potential benchmark for transparency across the...

Procter & Gamble (PG) is back in focus after recent share moves, as investors weigh its consumer staples profile against mixed return figures over different time frames and a current share price of $144.24. See our latest analysis for Procter & Gamble. Recent trading has been steady rather than sharp, with a 7 day share price return of 3.1% on top of a year to date share price return of 1.7%. However, the 1 year total shareholder return of 7.3% and 5 year total shareholder return of 22.4%...

In early January 2026, Intellia Therapeutics reported a fatal safety event and Grade 4 liver abnormalities in its Phase 3 MAGNITUDE ATTR-CM trial, prompting the FDA to place both MAGNITUDE and MAGNITUDE-2 studies on clinical hold while the company works with regulators on a path forward for nexiguran ziclumeran (nex-z). This setback for Intellia’s lead in vivo CRISPR program sharply elevates its regulatory and development risk profile, particularly given the company’s reliance on a...

SS Innovations International recently issued preliminary, unaudited results indicating fourth-quarter 2025 revenue of about US$15.0 million and full-year 2025 revenue of about US$43.0 million, both sharply higher than 2024 levels and driven by increased SSi Mantra surgical robot sales and installations. Alongside this growth, the company expanded its leadership bench by appointing veteran executive Milan Rao as both Chief Financial Officer and Global Chief Operating Officer, underscoring its...

If you are wondering whether Teva Pharmaceutical Industries is still reasonably priced after its recent run, this article will walk through what the current share price might be implying about value. Teva's stock last closed at US$32.47, with returns of 1.1% over 7 days, 9.0% over 30 days, 4.9% year to date, 54.8% over 1 year and 194.6% over 3 years. This naturally raises questions about how much of the story is already reflected in the price. Recent coverage has focused on Teva as investors...

Ultragenyx Pharmaceutical (RARE) is back in focus after reporting preliminary 2025 revenue guidance of US$672 million to US$674 million, which is above its prior range, alongside completing an FDA BLA submission for gene therapy candidate DTX401. See our latest analysis for Ultragenyx Pharmaceutical. The raised 2025 revenue guidance and DTX401 BLA completion come after a volatile period, with a 7 day share price return of 6.97% but a 30 day share price return of a 33.45% decline, and a 1 year...